Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells

作者
Łukasz Biegała,Arkadiusz Gajek,Izabela Szymczak-Pajor,Agnieszka Marczak,Agnieszka Śliwińska,Aneta Rogalska
出处
期刊:Scientific Reports [Nature Portfolio]
卷期号:13 (1): 22659-22659 被引量:25
标识
DOI:10.1038/s41598-023-50151-y
摘要

Abstract Olaparib is a PARP inhibitor (PARPi) approved for targeted treatment of ovarian cancer (OC). However, its efficacy is impeded by the inevitable occurrence of resistance. Here, we investigated whether the cytotoxic activity of olaparib could be synergistically enhanced in olaparib-resistant OC cells with BRCA2 reversion mutation by the addition of inhibitors of the ATR/CHK1 pathway. Moreover, we provide insights into alterations in the DNA damage response (DDR) pathway induced by combination treatments. Antitumor activity of olaparib alone or combined with an ATR inhibitor (ATRi, ceralasertib) or CHK1 inhibitor (CHK1i, MK-8776) was evaluated in OC cell lines sensitive (PEO1, PEO4) and resistant (PEO1-OR) to olaparib. Antibody microarrays were used to explore changes in expression of 27 DDR-related proteins. Olaparib in combination with ATR/CHK1 inhibitors synergistically induced a decrease in viability and clonogenic survival and an increase in apoptosis mediated by caspase-3/7 in all OC cells. Combination treatments induced cumulative alterations in expression of DDR-related proteins mediating distinct DNA repair pathways and cell cycle control. In the presence of ATRi and CHK1i, olaparib-induced upregulation of proteins determining cell fate after DNA damage (PARP1, CHK1, c-Abl, Ku70, Ku80, MDM2, and p21) was abrogated in PEO1-OR cells. Overall, the addition of ATRi or CHK1i to olaparib effectively overcomes resistance to PARPi exerting anti-proliferative effect in BRCA2MUT olaparib-resistant OC cells and alters expression of DDR-related proteins. These new molecular insights into cellular response to olaparib combined with ATR/CHK1 inhibitors might help improve targeted therapies for olaparib-resistant OC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李珂完成签到,获得积分10
2秒前
科研通AI65的应助被神奇蜥蜴采纳,获得10
2秒前
2秒前
123完成签到,获得积分10
3秒前
lx发布了新的文献求助20
3秒前
科研菜鸟完成签到,获得积分10
3秒前
wentong完成签到,获得积分10
3秒前
苹果熊猫完成签到,获得积分10
3秒前
3秒前
孔wj完成签到,获得积分10
3秒前
zz完成签到,获得积分10
4秒前
123完成签到,获得积分10
4秒前
细腻的香寒完成签到,获得积分10
4秒前
4秒前
5秒前
潇洒的傲柔完成签到,获得积分10
5秒前
xm完成签到,获得积分10
6秒前
sjy完成签到 ,获得积分20
7秒前
乂辛发布了新的文献求助10
8秒前
淡淡从蕾完成签到,获得积分10
8秒前
秋风的应助被piaoxinglin采纳,获得10
8秒前
lkyys发布了新的文献求助10
8秒前
皮皮虾完成签到 ,获得积分10
8秒前
biubiu完成签到,获得积分10
9秒前
9秒前
10秒前
11秒前
11秒前
11秒前
无极微光的应助被lx采纳,获得20
12秒前
呼呼呼完成签到 ,获得积分10
12秒前
努力成为科研大佬完成签到,获得积分10
12秒前
kuakuapizza完成签到 ,获得积分10
12秒前
12秒前
白瓜完成签到,获得积分10
13秒前
妞妞完成签到,获得积分10
13秒前
乐乐的应助被王雨荷采纳,获得10
14秒前
15秒前
rrs完成签到,获得积分10
16秒前
u711711完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190556
求助须知:如何正确求助?哪些是违规求助? 9577718
关于积分的说明 21854300
捐赠科研通 7789692
什么是DOI,文献DOI怎么找? 3436425
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483090